Clinical trials: Partial Seizures With Secondary Generalization
Epilepsy, Partial-onset Seizures
A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures
This study is to evaluate the long-term safety and tolerability of Lacosamide (LCM) 200 mg/day to LCM 600 mg/day taken in monotherapy in Japanese subjects who currently have partial-onset seizures with or without secondary…
- Trial name
- NCT02124564
- Testing
- Lacosamide
- Where
- 11 sites in Japan
- Volunteers
- 19 people
- Sponsor
- UCB Japan Co. Ltd.
Epilepsy
SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization
Male and female patients between 16 and 70 years of age who are diagnosed with epilepsy with partial seizures and are taking up to 3 medications for this medical condition will take part in a research study at approximately 85…
- Trial name
- NCT00136019
- Testing
- SPM 927
- Volunteers
- 400 people
- Sponsor
- UCB Pharma
Epilepsy, Partial Seizures
Efficacy and Safety of Levetiracetam in Partial Seizures Control, With or Without Secondary Generalization
The purpose of this study is to determine whether levetiracetam as adjunctive therapy is effective in the treatment of partial seizures, with or without secondary generalization, associated with refractory focal epilepsy.
- Trial name
- Mozart (NCT01392768)
- Testing
- Levetiracetam
- Volunteers
- 126 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Epilepsy
Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA)
This is a multicenter, non-interventional, prospective study. The observation period comprises at least 6 months, from the initiation of ESL add-on therapy in adult patients with partial-onset epilepsy not sufficiently controlled…
- Trial name
- NCT01532726
- Testing
- ESL
- Where
- Portugal
- Volunteers
- 56 people
- Sponsor
- Bial - Portela C S.A.
Epilepsy, Partial-onset Seizures
Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures
EP0024 is a Phase 3, multicenter, open-label study to evaluate the safety and tolerability of intravenous (iv) lacosamide (LCM).
- Trial name
- NCT02192814
- Testing
- Lacosamide (200 mg/20 mL)
- Where
- 5 sites in Japan
- Volunteers
- 9 people
- Sponsor
- UCB Japan Co. Ltd.
Epilepsy With Partial Onset Seizures With or Without Secondary Generalization, Psychoses
Epileptic Psychoses and Their Link With Ictal Emotions and Consciousness
Background : Psychiatric comorbidities are common in epilepsy, affecting 50 to 70% of patients, especially when the epilepsy is focal and drug-resistant.
- Conditions
- Epilepsy With Partial Onset Seizures With or Without Secondary Generalization, Psychoses, Epilepsy, Generalized
- Trial name
- ASPAIC (NCT06960811)
- Where
- France
- Volunteers
- 117 people
- Sponsor
- Central Hospital, Nancy, France
Focal Epilepsy With and Without Secondary Generalization
Real-world Clinical Response to Cenobamate Early add-on in France, Germany and Spain
Aim of the study is to better characterize the clinical profile of adjunctive cenobamate by collecting data from the current standard clinical practice in France, Germany, and Spain, to describe the real-world clinical response…
- Trial name
- NCT06716801
- Testing
- Cenobamate
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Partial Seizures With Secondary Generalization, Focal Epilepsy With Secondary Generalization
A Pilot Study: Focused Ultrasound Thalamotomy for the Prevention of Secondary Generalization in Focal Onset Epilepsy
The purpose of this study is to assess the safety and feasibility of unilateral focused ultrasound thalamotomy in adults with focal onset epilepsy whose medicines are not working well.
- Trial name
- NCT03417297
- Testing
- High Intensity Focused Ultrasound
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of North Carolina, Chapel Hill
Partial Onset Seizures
A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM)
This is a Non-interventional Prospective Study. Centres will enroll adult patients with partial onset seizures for whom the clinician has decided to initiate ZNS as an adjunctive therapy prior to the decision to take part in this…
- Trial name
- NCT01830868
- Testing
- Zonisamide tablets
- Where
- 37 sites in Austria, Denmark and 3 more
- Volunteers
- 104 people
- Sponsor
- Eisai Inc.
Epilepsy
A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures
Antiepileptic Drugs (AEDs) are the main treatment for epilepsy; however, only a limited number of AEDs are approved for use as monotherapy.
- Trial name
- NCT00699283
- Testing
- Brivaracetam
- Where
- 68 sites in United States, France and 4 more
- Volunteers
- 62 people
- Sponsor
- UCB Pharma
Epilepsy, Partial-onset Seizures
Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures
The purpose of this trial is to evaluate the safety and tolerability of long-term administration of Lacosamide at doses up to 400 mg/day in Japanese and Chinese adults with Epilepsy who have completed the Treatment and Transition…
- Trial name
- NCT01832038
- Testing
- Lacosamide
- Where
- 67 sites in China, Japan
- Volunteers
- 473 people
- Sponsor
- UCB Pharma SA
Epilepsy
A Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous SPM 927
The purpose of this trial was to evaluate the safety and tolerability of SPM 927 when given as iv infusions compared with oral administration of the same dose strengths in subjects who were receiving oral SPM 927 for partial…
- Trial name
- NCT00800215
- Volunteers
- 60 people
- Sponsor
- UCB Pharma
Epilepsies, Partial, Epilepsy, Tonic-Clonic
A Clinical Study on the Efficacy and Safety of Zonisamide as a First Add-On Treatment in Epileptic Seizures
This study primarily aims to assess the efficacy and safety of zonisamide when used as an adjunctive therapy for focal epilepsy. The main questions it aims to answer are: 1.
- Trial name
- NCT06967012
- Testing
- Oral Zonisamide Therapy
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Affiliated Hospital of Nantong University
Partial Seizures With or Without Secondary Generalization, Epilepsy
A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
The purpose of the study is to evaluate the safety and tolerability of intravenous (iv) brivaracetam (BRV) as adjunctive therapy administered as a replacement for oral BRV at doses ranging from BRV 50 mg/day to 200 mg/day in…
- Trial name
- NCT03685630
- Testing
- Brivaracetam
- Where
- 9 sites in Japan
- Volunteers
- 10 people
- Sponsor
- UCB Biopharma S.P.R.L.
Partial Seizures With or Without Secondary Generalization, Epilepsy
A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy
The purpose of the study is to evaluate the efficacy of brivaracetam (BRV) compared to placebo (PBO) as adjunctive treatment in subjects (>=16 to 80 years of age) with partial seizures with or without secondary generalization…
- Trial name
- NCT03083665
- Testing
- Brivaracetam
- Where
- 94 sites in China, Japan and 5 more
- Volunteers
- 449 people
- Sponsor
- UCB Biopharma SRL
Epilepsy With Partial Onset Seizures With or Without Secondary Generalization
Lacosamid-i.v.-Register
Lacosamide is a new antiepileptic drug (AED) marketed as Vimpat with three different formulations, tablets, oral syrup and a solution for intravenous infusion.
- Trial name
- LCM (NCT01620840)
- Testing
- Lacosamide 10mg/ml
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- University Hospital Schleswig-Holstein
Epilepsy, Simple Partial Seizures
Remegal Fixed Dose as Adjunctive Therapy in Patients With Partial Seizures
The purpose of this study is to determine weather Remegal in fixed dosage 1500 mg/daily is effictive and safe in patients with epilepsy with partial seizures
- Conditions
- Epilepsy, Simple Partial Seizures, Complex Partial Seizures, Partial Seizures With Secondary Generalization
- Trial name
- NCT01749046
- Testing
- Remegal
- Where
- 9 sites in Russia
- Volunteers
- 224 people
- Sponsor
- Valexfarm
Idiopathic Generalized Epilepsy, Partial Onset Seizures
A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy
The primary purpose of this study is to assess the retention rate of perampanel as a reliable proxy for overall effectiveness and tolerability in participants aged at least 12 years who are prescribed perampanel (for partial…
- Conditions
- Idiopathic Generalized Epilepsy, Partial Onset Seizures, Generalised Tonic-Clonic Seizures
- Trial name
- NCT04252846
- Testing
- Perampanel
- Where
- 36 sites in Denmark, France and 5 more
- Volunteers
- 191 people
- Sponsor
- Eisai Limited
Focal Epilepsy With and Without Secondary Generalization
Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy
This observational study aims to investigate how VIMPAT® is used as adjunctive therapy in clinical practice and will also evaluate the subsequent change in the drug load of patients after addition of VIMPAT® to their treatment…
- Trial name
- VICTOS (NCT01673282)
- Testing
- Lacosamide
- Where
- 42 sites in Austria, Germany
- Volunteers
- 315 people
- Sponsor
- UCB Pharma GmbH
Epilepsies, Partial
Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug
The purpose of this study is to systematically and prospectively collect data from patients with partial-onset seizures in routine clinical practice setting receiving adjunctive Vimpat®.
- Trial name
- VITOBA (NCT01098162)
- Where
- 113 sites in Germany
- Volunteers
- 576 people
- Sponsor
- UCB Pharma GmbH